Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RecruitingPhase 2Healthy volunteers welcome
Efficacy and Safety of Topical Clascoterone Cream 1% in Patients With Facial Acneiform Rosacea
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Men and women ages 18+. * Diagnosis of rosacea type 2 (papulopustular). * Available and willing to comply with study instructions and attend all study visits. * Able and willing to provide written and verbal informed consent. * Subject has used the same type and brand of make-up, other facial products, and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the baseline visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study. Exclusion Criteria: * Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy. * Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. * Pregnant, lactating, or is planning to become pregnant during the study. * Subject is currently enrolled in an investigational drug or device study. * Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline). * Study participant has facial hair that could interfere with the study assessments in the opinion of the investigator. * Study participant is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. * Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles. * Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.
About the study
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
What is being tested
- Clascoterone Cream 1% (drug)
Sponsor: Narrows Institute for Biomedical Research · Participants: 20 · Started: Mar 14, 2025
Contact the study team
- Kayla N Zafar, BA · Phone: 718-836-6600
Official record on ClinicalTrials.gov — NCT06952517
Locations in the U.S.
| New York | New York Harbor VA Brooklyn Campus, Brooklyn |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.